News briefing: Checkpoint reads out new interim mCSCC data; Taysha eyes $125M for its flash IPO
Checkpoint Therapeutics has read out updated interim Phase I data for its anti-PD-L1 antibody cosibelimab in a registration-enabling cohort of metastatic cutaneous squamous cell carcinoma patients. And the New York-based biotech plans to compete with rivals by “substantially lowering” costs.
The interim results, which were presented at ESMO, showed Checkpoint’s drug achieved a 51.4% objective response rate (ORR) and 13.5% complete response (CR) rate — nearly doubling the complete response rate observed during its last analysis, according to the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.